Open AccessBrigatinib Becomes Potential First-Line Option for ALK-Positive NSCLC
Publication year - 2018
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000547472.53965.9c
Subject(s) - crizotinib , line (geometry) , business , medicine , oncology , mathematics , lung cancer , geometry , malignant pleural effusion